title: Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty.
abstract: OBJECTIVE
  We report a case of neovascularization at the interface after a deep anterior lamellar keratoplasty and its regression after a single bevacizumab injection.
  
  
  METHODS
  Case report.
  
  
  RESULTS
  We present a case of neovascularization and bleeding at the interface 2 days after a deep anterior lamellar keratoplasty for herpetic disease that was completely reversed by a single injection of bevacizumab at the interface.
  
  
  CONCLUSIONS
  Corneal neovascularization is a typical sign of herpetic disease and one of the most important risk factors that can contribute to corneal graft failure. Close follow-up of patients at risk is necessary to detect and treat this complication as soon as possible to achieve a good outcome. Bevacizumab seems to be a successful and safe therapeutic option.
authors.affiliation: Department of Ophthalmology, Ramón y Cajal Hospital, Madrid, Spain. elejarrin@hotmail.com
authors.forename: Elena
authors.initials: E
authors.lastname: Jarrín
authors.forename: Diego
authors.initials: D
authors.lastname: Ruiz-Casas
authors.forename: Antonio
authors.initials: A
authors.lastname: Mendivil
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy*; D016039:Corneal Transplantation / Q000009:adverse effects*; D006801:Humans; D007634:Keratitis / Q000601:surgery; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab